Login
Navigate Fool.com
Will DVAX beat
the market?
Community Rating: 3 Stars: Appealing

1.13 0.09 (8.65%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $1.04
Previous Close $1.04
Daily Range $1.02 - $1.14
52-Week Range $0.99 - $5.10
Market Cap $206.7M
P/E Ratio -2.54
Dividend (Yield) $0.00 (0.0%)
Volume 6,738,204
Average Daily Volume 3,490,922
Current FY EPS -$0.40

How do you think DVAX
will perform against the market?

Top DVAX Bull/Bear Pitches

 

foolphighter (0)
Submitted January 12, 2007

Small biotech has recently released promising late stage trial results for its HEPLSAV hepatitus B vaccine drug, as well as encouraging earlier stage results for its TLR9 agonist in cancer indications … More

0 Replies Reply Report this Post
 

hawkider (< 20)
Submitted December 7, 2006

House of cards

0 Replies Reply Report this Post

News & Commentary

This Week in Biotech

Clinical updates, an FDA approval, a drug purchase, and a "for-sale" sign in a well-known biotech's front yard dominates this week's top stories.

SHAREHOLDER ALERT: Brower Piven Announces an Investigation of Dynavax Technologies Corporation for P

3 Horrendous Health-Care Stocks This Week

Had a bad week? Seeing how horribly these stocks performed might make you feel better by comparison.

Law Firm Finkelstein Thompson LLP Announces Investigation of Dynavax Technologies Corp.

Why Dynavax Technologies Shares Were Eviscerated

Things go from bad to worse when the Food and Drug Administration sends Dynavax packing.

Market Wrap for Monday, June 10: Stocks Little Changed in Quiet Trade

Hot Off the Press: Dynavax Tumbles 30%

What caused this biotech to crash this morning?

U.S. HOT STOCK FUTURES: HOT STOCKS TO WATCH

Here's What This $5 Billion Hedge Fund Has Been Buying

It can pay off to keep an eye on the big guys.

5 Worst Biotechs of 2013

A simple list of five of the worst biotech performers through May.

See More DVAX News...

Sector

Healthcare

Industry

Drugs

Dynavax Technologies Corp (DVAX) Description

A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory. Website: http://www.dynavax.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks